Internuclear Ophthalmoplegia and Multiple Sclerosis: a Multicenter Retrospective Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- Analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis.
Study Overview
Brief Summary
Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet the diagnostic criteria for MS at the time of the internuclear ophthalmoplegia episode but subsequently convert to MS. Studying this specific clinical situation may help enable earlier diagnosis of MS.
The objective is to analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis and to identify factors associated with this conversion.
The study hypothesis is that the presence of internuclear ophthalmoplegia is highly suggestive of multiple sclerosis, particularly when cerebrospinal fluid-specific oligoclonal bands are present.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with internuclear ophthalmoplegia listed as a primary or associated diagnosis
- •Patients hospitalized in a neurology department
Exclusion Criteria
- •- Patients under 18 years of age
Arms & Interventions
Internuclear ophthalmoplegia
This is a retrospective cohort study involving patients who have experienced internuclear ophthalmoplegia. For each patient, it is determined whether a diagnosis of multiple sclerosis was established or not.
Outcomes
Primary Outcomes
Analyze the proportion of patients with isolated internuclear ophthalmoplegia who convert to multiple sclerosis.
Time Frame: 1 year
Proportion of patients with isolated internuclear ophthalmoplegia who converted to multiple sclerosis during follow-up.
Secondary Outcomes
No secondary outcomes reported